Humabody® Drug Conjugates
IgG-based Antibody Drug Conjugates (ADCs), are a highly promising format for the development of new cancer therapies. The biggest challenge with these constructs is that it is often necessary to dose very close to the Maximum Tolerated Dose giving these compounds a very narrow Therapeutic Index. Our unique Humabody® Drug Conjugate (HDC) approach offers increased specificity and superior toxicology profiles leading to an improved Therapeutic index (enabled by a “high dose, hit hard and leave” approach). We have successfully demonstrated in vivo that Humabodies rapidly penetrate and accumulate within tumours resulting in a greatly increased tumour to blood ratio compared to IgGs delivering highly potent tumour killing.
A half-life extended biparatopic PSMA-specific Humabody® Drug Conjugate (HDC) demonstrating superior tumour targeting, enhanced internalisation and highly efficient accumulation in target-positive tumours is now available for partnering or out-license.